AMBRA1 Promotes TGFβ Signaling via Nonproteolytic Polyubiquitylation of Smad4

Liu Jinquan, Yuan Bo, Cao Jin, Luo Hongjie, Gu Shuchen, Zhang Mengdi, Ding Ran, Zhang Long, Zhou Fangfang, Hung Mien-Chie, Xu Pinglong, Lin Xia, Jin Jianping, Feng Xin-Hua

Journal:CANCER RESEARCH

IF:12.7

DOI:10.1158/0008-5472.CAN-21-0431

PMID:

Published:2021-10-01

research field:肿瘤学分子生物学细胞生物学

Abstract

This study identifies AMBRA1 as a novel regulator of TGFβ signaling and breast cancer metastasis, supporting further exploration of AMBRA1 as a target for cancer therapy. Transforming growth factor β (TGFβ) is prometastatic in advanced cancers and its biological activities are mainly mediated by the Smad family of proteins. Smad4 is the central signal transducer and transcription factor in the TGFβ pathway, yet the underlying mechanisms that govern transcriptional activities of Smad4 are not fully understood. Here, we show that AMBRA1, a member of the DDB1 and CUL4-associated factor (DCAF) family of proteins, serves as the substrate receptor for Smad4 in the CUL4-RING (CRL4) ubiquitin ligase complex. The CRL4-AMBRA1 ubiquitin ligase mediates nonproteolytic polyubiquitylation of Smad4 to enhance its transcriptional functions. Consequently, AMBRA1 potentiated TGFβ signaling and critically promoted TGFβ-induced epithelial-to-mesenchymal transition, migration, and invasion of breast cancer cells. Mouse models of breast cancer demonstrated that AMBRA1 promotes metastasis. Collectively, these results show that CRL4-AMBRA1 facilitates TGFβ-driven metastasis by increasing Smad4 polyubiquitylation, suggesting AMBRA1 may serve as a new therapeutic target in metastatic breast cancer. Significance: This study identifies AMBRA1 as a novel regulator of TGFβ signaling and breast cancer metastasis, supporting further exploration of AMBRA1 as a target for cancer therapy.

本文使用的Yeasen产品

购物车
客服
转染试用